| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ERVFRD-1 |
| Uniprot No | P60508 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 16-350aa |
| 氨基酸序列 | Endogenous retrovirus group FRD member 1;Envelope polyprotein;HERV-FRD;HERV-FRD_6p24.1 provirus ancestral Env polyprotein;SU;TM |
| 分子量 | 38.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人ERVFRD-1蛋白的3-4篇参考文献示例(文献信息为虚构示例，仅供参考格式)：
---
1. **文献名称**：*"Expression and functional analysis of recombinant human ERVFRD-1 in placental syncytium formation"*
**作者**：C. Knopp, T. et al.
**摘要**：该研究通过哺乳动物细胞表达系统成功纯化重组人ERVFRD-1蛋白，并证实其通过介导细胞膜融合促进合胞体滋养层形成，为胎盘发育机制提供了分子层面的证据。
---
2. **文献名称**：*"Evolutionary conservation of ERVFRD-1 as a fusogenic protein in mammalian placentation"*
**作者**：Malik, H.S. et al.
**摘要**：作者分析了ERVFRD-1在多种哺乳动物中的进化保守性，发现其基因序列与逆转录病毒包膜蛋白高度同源，提示其在胎盘形成中的关键作用可能源于远古病毒感染事件。
---
3. **文献名称**：*"Dysregulation of ERVFRD-1 in preeclampsia: Insights from recombinant protein-based assays"*
**作者**：Zhang, Y. et al.
**摘要**：研究利用重组ERVFRD-1蛋白进行体外实验，发现先兆子痫患者胎盘组织中该蛋白表达显著降低，可能影响滋养层细胞融合功能，导致胎盘功能障碍。
---
4. **文献名称**：*"Structural characterization of recombinant ERVFRD-1 and its receptor interaction"*
**作者**：Dunlap, K.A. et al.
**摘要**：通过X射线晶体学解析了重组ERVFRD-1的三维结构，并鉴定其与细胞表面受体SLC1A5的结合域，揭示了其介导细胞融合的分子机制。
---
(注：以上文献为示例，实际引用需以真实发表的论文为准。)
Recombinant human ERVFRD-1 protein is derived from the endogenous retroviral gene *ERVFRD-1* (also termed *Suppressyn*), a member of the human endogenous retrovirus (HERV) family HERV-W. Integrated into the human genome during evolution, HERVs constitute ~8% of human DNA and have been implicated in physiological and pathological processes. ERVFRD-1 is specifically expressed in placental trophoblasts and is thought to play a role in cell-cell fusion, a critical process in syncytiotrophoblast formation during early embryonic development. It shares functional homology with Syncytin-1. another HERV-derived fusogenic protein, but acts as its competitive inhibitor by binding to the same receptor, ASCT2. This regulatory interplay may fine-tune trophoblast fusion and placental morphogenesis.
The recombinant form of ERVFRD-1 is typically produced in vitro using eukaryotic expression systems to ensure proper post-translational modifications. Researchers utilize it to study mechanisms of placental development, HERV-mediated fusogenicity, and viral-host interactions. Dysregulation of ERVFRD-1 has been linked to pregnancy complications, such as preeclampsia and fetal growth restriction, making it a potential biomarker or therapeutic target. Additionally, its unique receptor-binding properties spark interest in antiviral drug development and engineered cell fusion applications. Structural studies focus on its surface glycoprotein domains, including fusion peptides and immunosuppressive regions, to elucidate evolutionary adaptations and functional versatility.
×
